Abstract:

Purpose: In the treatment of refracteric diabetic macula edema (DMA), intravitreal bevacizumab injection was intended to study its effects on the visual accuracy and central fovea thickness. Tools and Methods: In our clinic's retina unit between January 2010-February 2011 optical coherence tomography (OCT) measurements were taken into the 20 eye study scope of 15 patients with a diffuse DMO of more than 350 μm of central fovea thickness. The patient was followed for an average of 9 months. Injections of 1.25 mg/0.05 ml bevacizumab were made from the Pars plan. Before the injection of the incidents, the visual accuracy (log-MAR) in the 1st, 3rd and 6th months, the front segment, fundus and OKT findings were evaluated. Results: 6 of the fifteen patients (40%) were women, 9 (60%) were men and their average age was 51.4±7.4. The patient’s average vision accuracy (log-MAR) was 1.0±0.67 before treatment; 0.8±0.5 in the 1st month after treatment; 0.7±0.4 in the 3rd month; 0.6±0.4 in the 6th month. The improved best vision accuracy after intravenous bevacizumab injection increased by 10 (50%) preference, 7 (35) preference did not change, and 3 (15%) preference was reduced. The pre-application average central fovea thickness was 690±90μm while 300±84μm in the 1st month, 290±84 μm in the 3rd month and 260±41μm in the 6th month. According to OKT results in the first, third and six months before and after the injection, 12 preferred (60%) macular obesity was reduced, 5 preferred (25%) changes were not observed, and 3 preferred (15%) increased. In the follow-up period, 5 eye injections (25%) should be repeated. The result: in our patients with refracter diffuse DMO, intravitreal bevacizumab is provided with an anatomical correction that can be detected with OKT, in addition to the prevention of vision loss.

Keywords: